Clinical Trials Browser

Phase 2 × Carcinoma, Renal Cell × IT-101 × Clear all

NCT02187302 2020-05-28

CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

Phase 2 Completed

Carcinoma, Renal Cell